GALR2, galanin receptor 2, 8811

N. diseases: 41; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0432215
Disease: Progressive pseudorheumatoid dysplasia
Progressive pseudorheumatoid dysplasia 		0.010 Biomarker disease BEFREE In the present study, we discovered that the expression of GALR1, rather than GALR2/3, was upregulated with a region-specific pattern in the prefrontal cortex (PFC) of E2 withdrawal induced PPD model rats. 30487761 2018
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.020 Biomarker disease BEFREE Irrespective of the mechanism(s) by which galanin alters EAE disease activity, our findings imply that galanin/GalR2 agonists may have future therapeutic implications for MS. 19717462 2009
CUI: C0036572
Disease: Seizures
Seizures 		0.020 Biomarker phenotype BEFREE NAX 810-2, a galanin receptor subtype 2 (GalR2)-preferring galanin analog, possesses 15-fold greater affinity for GalR2 over GalR1 and protects against seizures in the mouse 6 Hz, corneal kindling, and Frings audiogenic seizure models. 28098336 2017
CUI: C0751791
Disease: Reflex Epilepsy, Audiogenic
Reflex Epilepsy, Audiogenic 		0.010 Biomarker disease BEFREE NAX 810-2, a galanin receptor subtype 2 (GalR2)-preferring galanin analog, possesses 15-fold greater affinity for GalR2 over GalR1 and protects against seizures in the mouse 6 Hz, corneal kindling, and Frings audiogenic seizure models. 28098336 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.020 Biomarker disease BEFREE Others showed that GALR2 could induce apoptosis in neuroblastoma cells with wild-type p53, whereas GALR2 stimulated proliferation in small cell lung cancer. 19276245 2009
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.020 Biomarker disease BEFREE Others showed that GALR2 could induce apoptosis in neuroblastoma cells with wild-type p53, whereas GALR2 stimulated proliferation in small cell lung cancer. 19276245 2009
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.020 Biomarker disease BEFREE Others showed that GALR2 could induce apoptosis in neuroblastoma cells with wild-type p53, whereas GALR2 stimulated proliferation in small cell lung cancer. 19276245 2009
CUI: C0149925
Disease: Small cell carcinoma of lung
Small cell carcinoma of lung 		0.010 Biomarker disease BEFREE Others showed that GALR2 could induce apoptosis in neuroblastoma cells with wild-type p53, whereas GALR2 stimulated proliferation in small cell lung cancer. 19276245 2009
CUI: C0011603
Disease: Dermatitis
Dermatitis 		0.010 Biomarker disease BEFREE Our data indicate that galanin receptor 3, but not galanin receptor 2, plays an important role in psoriasis-like skin inflammation. 28844939 2018
CUI: C3875321
Disease: Inflammatory dermatosis
Inflammatory dermatosis 		0.010 Biomarker disease BEFREE Our data indicate that galanin receptor 3, but not galanin receptor 2, plays an important role in psoriasis-like skin inflammation. 28844939 2018
CUI: C0031511
Disease: Pheochromocytoma
Pheochromocytoma 		0.020 AlteredExpression disease BEFREE Our previous study has shown that overexpression of ETS-1 increases the expression of GalR2 in PC12 phaeochromocytoma cells. 31327148 2019
CUI: C4551683
Disease: Adrenal Gland Pheochromocytoma
Adrenal Gland Pheochromocytoma 		0.010 AlteredExpression disease BEFREE Our previous study has shown that overexpression of ETS-1 increases the expression of GalR2 in PC12 phaeochromocytoma cells. 31327148 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 Biomarker group BEFREE Pharmacological analysis of tumor membrane homogenates with GAL and the specific GAL receptor GalR2 agonist, AR-M1896, revealed that the GAL receptor GalR1 is most likely the receptor responsible for the observed GAL binding in the glioblastomas. 12734662 2003
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.010 Biomarker disease BEFREE Pharmacological analysis of tumor membrane homogenates with GAL and the specific GAL receptor GalR2 agonist, AR-M1896, revealed that the GAL receptor GalR1 is most likely the receptor responsible for the observed GAL binding in the glioblastomas. 12734662 2003
CUI: C0003467
Disease: Anxiety
Anxiety 		0.040 Biomarker disease BEFREE Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. 18554714 2008
CUI: C0003469
Disease: Anxiety Disorders
Anxiety Disorders 		0.040 Biomarker group BEFREE Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. 18554714 2008
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.320 Biomarker disease BEFREE Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. 18554714 2008
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.320 Biomarker disease PSYGENET Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. 18554714 2008
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.020 Biomarker disease BEFREE Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. 18554714 2008
CUI: C0344315
Disease: Depressed mood
Depressed mood 		0.020 Biomarker phenotype BEFREE Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. 18554714 2008
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.010 Biomarker disease BEFREE Similarly NKX2-5, SPOCK2, SLC16A12, DPYS and GALR2 are candidate biomarkers for colon cancer (methylation range 60%-95%) and GALR2 hypermethylation showed a sensitivity of 85% and specificity of 95%. 18446232 2008
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.010 Biomarker disease BEFREE Similarly NKX2-5, SPOCK2, SLC16A12, DPYS and GALR2 are candidate biomarkers for colon cancer (methylation range 60%-95%) and GALR2 hypermethylation showed a sensitivity of 85% and specificity of 95%. 18446232 2008
CUI: C1168401
Disease: Squamous cell carcinoma of the head and neck
Squamous cell carcinoma of the head and neck 		0.050 Biomarker disease BEFREE SST methylation in 81% of HNSCC tumor specimens significantly correlated with tumor size (P = 0.043), stage (P = 0.008), galanin receptor type 2 (GALR2) methylation (P = 0.041), and tachykinin-1 (TAC1) (P = 0.040). 25734919 2015
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 AlteredExpression group BEFREE SSTR1 hypermethylation in 64% of cases was correlated with tumor size (P = 0.037), stage (P = 0.037), SST methylation (P < 0.001), and expression of galanin (P = 0.03), GALR2 (P = 0.014), TAC1 (P = 0.023), and tachykinin receptor type 1 (TACR1) (P = 0.003). 25734919 2015
CUI: C0086132
Disease: Depressive Symptoms
Depressive Symptoms 		0.010 GeneticVariation phenotype BEFREE The effects of rs948854 and rs4432027 SNPs, both located within the promoter region of the GAL gene, rs11665337 in the GALR1 receptor, and rs8836 in the GALR2 receptor on depressive symptoms were examined. 28987550 2018